HanAll's Partner HBM Announces Positive Topline Results from Phase 2 of Batoclimab in MG
HanAll Biopharma (KRX: 009420.KS) today announced that its partner for HL161 (batoclimab) & HL036 (tanfanercept), Harbour BioMed, reported positive topline results from Phase 2 of batoclimab in MG.
- HBM press release link: https://www.harbourbiomed.com/news/157.html
NextHanAll's Partner HBM Announces Last Patient Dosing of Phase 1b/2a of Batoclimab in NMOSD
PrevHanAll Biopharma Reports First Quarter 2021 Financial Results